Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Insulin degludec: a new ultra-longacting insulin.

Tahrani AA, Bailey CJ, Barnett AH.

Lancet. 2012 Apr 21;379(9825):1465-7. doi: 10.1016/S0140-6736(12)60527-3. No abstract available.

PMID:
22521058
[PubMed - indexed for MEDLINE]
2.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
[PubMed - indexed for MEDLINE]
3.

What are editors for?

Burch D, Mafham M, Yudkin JS.

Lancet. 2012 Jun 16;379(9833):2240. doi: 10.1016/S0140-6736(12)60977-5. No abstract available.

PMID:
22704168
[PubMed - indexed for MEDLINE]
4.

Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

Keating GM.

Drugs. 2013 May;73(6):575-93. doi: 10.1007/s40265-013-0051-1. Review.

PMID:
23620200
[PubMed - indexed for MEDLINE]
5.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
[PubMed - indexed for MEDLINE]
6.

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, King A, Mersebach H, Davies M.

Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.

PMID:
22933438
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.

Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.

Eur J Endocrinol. 2012 Aug;167(2):287-94. doi: 10.1530/EJE-12-0293. Epub 2012 Jun 1. Erratum in: Eur J Endocrinol. 2012 Sep;167(3):453.

PMID:
22660026
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.

Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.

Pediatr Diabetes. 2013 May;14(3):196-202. doi: 10.1111/pedi.12012. Epub 2013 Jan 4.

PMID:
23289822
[PubMed - indexed for MEDLINE]
9.

Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes.

Nguyen TM, Renukuntla VS, Heptulla RA.

Diabetes Care. 2010 Aug;33(8):1750-2. doi: 10.2337/dc10-0169. Epub 2010 May 26.

PMID:
20504899
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.

Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI.

Diabet Med. 2012 Jun;29(6):716-20. doi: 10.1111/j.1464-5491.2011.03547.x.

PMID:
22150786
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.

Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.

Diabet Med. 2013 Feb;30(2):216-25. doi: 10.1111/dme.12041.

PMID:
23094597
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.

Shanmugasundar G, Bhansali A, Walia R, Dutta P, Upreti V.

Indian J Med Res. 2012;135:78-83.

PMID:
22382187
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Insulin degludec: a new insulin for today?

Hitman GA.

Diabet Med. 2013 Nov;30(11):1267. doi: 10.1111/dme.12319. No abstract available.

PMID:
24134602
[PubMed - indexed for MEDLINE]
14.

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C.

Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7.

PMID:
21396703
[PubMed - indexed for MEDLINE]
15.

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.

Ohta A, Arai K, Nishine A, Sada Y, Kato H, Fukuda H, Asai S, Nagai Y, Katabami T, Tanaka Y.

Endocr J. 2013;60(2):173-7. Epub 2012 Oct 6.

PMID:
23047542
[PubMed - indexed for MEDLINE]
Free Article
16.

The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin.

Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA.

Diabetes Care. 2012 Apr;35(4):690-2. doi: 10.2337/dc11-0732. Epub 2012 Feb 28.

PMID:
22374642
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes.

Shanik MH.

Diabetes Technol Ther. 2012 Jun;14(6):533-9. doi: 10.1089/dia.2011.0256. Epub 2012 Feb 24. Review.

PMID:
22364142
[PubMed - indexed for MEDLINE]
18.

Insulin degludec: overview of a novel ultra long-acting basal insulin.

Gough SC, Harris S, Woo V, Davies M.

Diabetes Obes Metab. 2013 Apr;15(4):301-9. doi: 10.1111/dom.12052. Epub 2013 Jan 29. Review.

PMID:
23240573
[PubMed - indexed for MEDLINE]
19.

Ultra-long-acting insulins for a lifestyle-related pandemic.

Kudva YC, Basu A.

Lancet. 2011 Mar 12;377(9769):880-1. doi: 10.1016/S0140-6736(11)60097-4. No abstract available.

PMID:
21396704
[PubMed - indexed for MEDLINE]
20.

Audit of insulin detemir in pregnancy: a retrospective case series.

Shenoy VV, Cook SJ, Parry AF, McIntyre HD.

Diabet Med. 2012 Jul;29(7):958-9. doi: 10.1111/j.1464-5491.2012.03580.x. No abstract available.

PMID:
22248154
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk